RMD
RESMED INC
$208.05
-0.45%
$30.2B
No data for this timeframe.
Vol
Market Cap$30.2B
Cap SizeLarge Cap
Analyst ConsensusBuy (62%)
Inst. Holders9 funds
Inst. Value$6.2B
Inst. Activity3 buys / 1 sells
Insider Activity0B / 11S
Insider Net $-$7.0M
Reddit Sentiment40° Cool
SEC Reports7
Congressional1 trades
Exchange OTC·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000943819·Prev Close $208.98
Recent Activity
May 19, 2026
SEC
Resmed reports fiscal Q3 2026 EPS of $2.86, a 1.4% miss vs consensus of $2.90. The miss breaks a streak of four consecut
PRESS-RELEASE — Impact 5/10
May 19, 2026
earnings
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
<p align="left">SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today ann
May 7, 2026
Insider
Farrell Michael J. sold 4,991 shares
Chairman and CEO @ $146.34 ($730.4K)
May 7, 2026
Insider
Farrell Michael J. sold 4,991 shares
Chairman and CEO @ $207.82 ($1.0M)
May 7, 2026
Insider
Farrell Michael J. sold 4,991 shares
Chairman and CEO @ $0.00 ($0.00)
Apr 13, 2026
Congress
Ro Khanna buy
$1,001 - $15,000 — House
Apr 9, 2026
SEC
ResMed insiders sold $1.8M in shares over a 7-day period, led by CEO Michael Farrell's $1.13M open-market sale following
CLUSTER — Impact 3/10
Apr 3, 2026
SEC
Two corporate insiders at ResMed sold shares in a coordinated 7-day window, including CFO Brett Sandercock selling $224K
CLUSTER — Impact 5/10
Price Targets
$270.60
+30.1% upside
Strong Buy
Current $208.05
Low $180.00
Median $286.00
High $340.00
15 analysts
$180.00
$340.00
Analyst Ratings
4Strong Buy
12Buy
9Hold
0Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 1, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 1, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Apr 27, 2026 | Keybanc | MAINTAIN | Overweight → Overweight |
| Apr 9, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Feb 2, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.90 | $2.87 — $2.99 | 14% YoY | 10 |
| Next Q | $2.87 | $2.78 — $2.95 | 12% YoY | 9 |
| Current FY | $11.08 ▲ +0.5% | $10.42 — $11.23 | 16% YoY | 13 |
| Next FY | $12.20 | $11.74 — $12.58 | 10% YoY | 13 |
Latest Reports
BEARISH
PRESS-RELEASE
5/10
Resmed reports fiscal Q3 2026 EPS of $2.86, a 1.4% miss vs consensus of $2.90. The miss breaks a streak of four consecut
May 19, 2026
NEUTRAL
CLUSTER
3/10
ResMed insiders sold $1.8M in shares over a 7-day period, led by CEO Michael Farrell's $1.13M open-market sale following
Apr 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.5B | — |
| MORGAN STANLEY | $696.5M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $265.8M | NEW |
| NORGES BANK | $249.1M | NEW |
| BANK OF AMERICA CORP | $200.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 7, 2026 | Farrell Michael | M | $730.4K |
| May 7, 2026 | Farrell Michael | SELL | $1.0M |
| May 7, 2026 | Farrell Michael | M | $0.00 |
| Apr 7, 2026 | Farrell Michael | M | $730.4K |
| Apr 7, 2026 | Farrell Michael | SELL | $1.1M |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
9 institutional holders with $6.2B total value (25,687,059 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 18,882,403 | $4.5B | 73.5% | — |
| 2 | MORGAN STANLEY | 2,891,697 | $696.5M | 11.3% | ADD +25.0% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,103,459 | $265.8M | 4.3% | NEW |
| 4 | NORGES BANK | 1,034,037 | $249.1M | 4.0% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 831,024 | $200.2M | 3.2% | — |
| 6 | FMR LLC | 415,813 | $100.2M | 1.6% | TRIM -52.8% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 304,480 | $73.3M | 1.2% | DOUBLED +425.0% |
| 8 | WELLS FARGO & COMPANY/MN | 151,192 | $36.4M | 0.6% | — |
| 9 | Mawer Investment Management Ltd. | 72,954 | $17.6M | 0.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 2,313,138 | 2,891,697 | +25.0% | $696.5M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,034,037 | — | $249.1M | 2025-Q4 |
| FMR LLC | TRIM | 880,306 | 415,813 | -52.8% | $100.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 58,000 | 304,480 | +425.0% | $73.3M | 2025-Q4 |
| UBS Group AG | ADD | 549,356 | 906,730 | +65.1% | $248.2M | 2025-Q3 |
| FMR LLC | DOUBLED | 344,799 | 880,306 | +155.3% | $241.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 103,000 | 58,000 | -43.7% | $15.9M | 2025-Q3 |
| NORGES BANK | EXIT | 1,187,798 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | TRIM | 4,139,611 | 2,660,233 | -35.7% | $686.3M | 2025-Q2 |
| NORGES BANK | NEW | — | 1,187,798 | — | $306.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 54,000 | 103,000 | +90.7% | $26.6M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 247,700 | 54,000 | -78.2% | $12.1M | 2025-Q1 |
| NORGES BANK | EXIT | 518,628 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 235,639 | 567,986 | +141.0% | $129.9M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 84,000 | 247,700 | +194.9% | $56.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 483,835 | 230,278 | -52.4% | $52.7M | 2024-Q4 |
| MORGAN STANLEY | ADD | 3,396,522 | 4,476,564 | +31.8% | $1.1B | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 924,047 | — | $225.6M | 2024-Q3 |
4 unique insiders with 11 transactions. Net insider value: -$7.0M ($0.00 bought, $7.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 7, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $146.34 | $730.4K |
| May 7, 2026 | Farrell Michael J. | Chairman and CEO | SELL | 4,991 | $207.82 | $1.0M |
| May 7, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $0.00 | $0.00 |
| Apr 7, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $146.34 | $730.4K |
| Apr 7, 2026 | Farrell Michael J. | Chairman and CEO | SELL | 4,991 | $225.50 | $1.1M |
| Apr 7, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $0.00 | $0.00 |
| Apr 1, 2026 | FARRELL PETER C | Director | SELL | 2,000 | $225.00 | $450.0K |
| Apr 1, 2026 | Sandercock Brett | Chief Financial Officer | SELL | 1,000 | $224.31 | $224.3K |
| Mar 9, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $146.34 | $730.4K |
| Mar 9, 2026 | Farrell Michael J. | Chairman and CEO | SELL | 4,991 | $251.03 | $1.3M |
| Mar 9, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $0.00 | $0.00 |
| Mar 4, 2026 | FARRELL PETER C | Director | SELL | 2,000 | $260.22 | $520.4K |
| Mar 2, 2026 | Sandercock Brett | Chief Financial Officer | SELL | 1,000 | $254.30 | $254.3K |
| Feb 9, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $0.00 | $0.00 |
| Feb 9, 2026 | Farrell Michael J. | Chairman and CEO | SELL | 4,991 | $273.78 | $1.4M |
| Feb 9, 2026 | Farrell Michael J. | Chairman and CEO | M | 4,991 | $146.34 | $730.4K |
| Feb 4, 2026 | Rider Michael J | Global General Counsel | SELL | 50 | $260.00 | $13.0K |
| Feb 4, 2026 | FARRELL PETER C | Director | SELL | 2,000 | $251.31 | $502.6K |
| Feb 2, 2026 | Sandercock Brett | Chief Financial Officer | SELL | 1,000 | $257.03 | $257.0K |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 4 neutral. Avg impact: 4.1/10.
BEARISH
PRESS-RELEASE
5/10
Resmed reports fiscal Q3 2026 EPS of $2.86, a 1.4% miss vs consensus of $2.90. The miss breaks a str
May 19, 2026
NEUTRAL
CLUSTER
3/10
ResMed insiders sold $1.8M in shares over a 7-day period, led by CEO Michael Farrell's $1.13M open-m
Apr 9, 2026
BEARISH
CLUSTER
5/10
Two corporate insiders at ResMed sold shares in a coordinated 7-day window, including CFO Brett Sand
Apr 3, 2026
NEUTRAL
PRESS-RELEASE
2/10
ResMed issued a press release announcing the upcoming date for its Q3 FY2026 earnings release on Apr
Apr 1, 2026
NEUTRAL
CLUSTER
4/10
ResMed CEO Michael J. Farrell exercised stock options and sold 4,991 shares in the open market for a
Mar 11, 2026
NEUTRAL
CLUSTER
3/10
Two ResMed insiders, including CFO Brett Sandercock, sold shares in the past week, totaling $774,740
Mar 5, 2026
BULLISH
INST-CLUSTER
7/10
Three major institutions — Morgan Stanley, Norges Bank, and RenTech — collectively added $369.9M in
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (62% buy). Based on 26 analysts: 4 strong buy, 12 buy, 9 hold, 0 sell, 1 strong sell.
Analyst Price Targets
$270.60 mean target
+30.1% upside
Strong Buy (2.11)
$180.00 Low
$340.00 High
| Metric | Value |
|---|---|
| Current Price | $208.05 |
| Target Low | $180.00 |
| Target Mean | $270.60 |
| Target Median | $286.00 |
| Target High | $340.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (2.11) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.90 | $2.87 | $2.99 | 13.8% | +0.5% | 9↑ 4↓ | $1.5B | 8.4% | 10 |
| Next Q 2026-09-30 |
$2.87 | $2.78 | $2.95 | 12.4% | +0.0% | 3↑ 4↓ | $1.4B | 7.4% | 9 |
| Current FY 2026-06-30 |
$11.08 | $10.42 | $11.23 | 16.0% | +0.5% | 16↑ 3↓ | $5.6B | 9.8% | 13 |
| Next FY 2027-06-30 |
$12.20 | $11.74 | $12.58 | 10.1% | +0.2% | 11↑ 8↓ | $6.1B | 7.4% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.901 | |
| 7d ago | $2.901 | |
| 30d ago | $2.887 | +0.013 |
| 60d ago | $2.889 | +0.011 |
| 90d ago | $2.893 | +0.007 |
7 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 1, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 1, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 27, 2026 | Keybanc | MAINTAIN | Overweight | Overweight |
| Apr 9, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 30, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Jan 30, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 30, 2026 | Stifel | MAINTAIN | Hold | Hold |
| Dec 18, 2025 | Stifel | MAINTAIN | Hold | Hold |
| Dec 16, 2025 | Baird | DOWNGRADE | Outperform | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 12 | 9 | 0 | 1 | 62% | |
| Apr 1, 2026 | 4 | 11 | 9 | 0 | 1 | 60% | |
| Mar 1, 2026 | 4 | 12 | 8 | 0 | 1 | 64% | |
| Feb 1, 2026 | 4 | 12 | 8 | 0 | 1 | 64% | |
| Jan 1, 2026 | 4 | 12 | 8 | 0 | 1 | 64% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Resmed Inc | May 13, 2026 (31d) |
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 22, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Retired and now I have to worry about RMD Distribution
▲ 1
💬 1
⚡ 0.0
May 19, 2026
earnings
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
<p align="left">SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive
May 12, 2026
short_volume
Short Volume: RMD — 57.9% short (0.3M / 0.6M)
Short: 325,290 | Exempt: 1,321 | TRF Vol: 561,430 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: RMD — 57.0% short (0.4M / 0.8M)
Short: 447,707 | Exempt: 0 | TRF Vol: 785,258 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: RMD — 60.6% short (0.3M / 0.6M)
Short: 339,517 | Exempt: 7 | TRF Vol: 560,345 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: RMD — 55.2% short (0.6M / 1.0M)
Short: 568,248 | Exempt: 983 | TRF Vol: 1,028,901 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: RMD — 77.8% short (1.2M / 1.5M)
Short: 1,181,253 | Exempt: 5,846 | TRF Vol: 1,517,447 | Short Ratio: 77.8% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
other
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
<p>SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and
Apr 30, 2026
earnings
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
<p align="left"><em>Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at </em><a href="https://www.globenewswire.com
Apr 30, 2026
earnings_calendar
RMD Q3 2026 Earnings Scheduled — 2026-04-30
Apr 30, 2026
short_volume
Short Volume: RMD — 75.1% short (0.5M / 0.7M)
Short: 503,852 | Exempt: 48 | TRF Vol: 670,518 | Short Ratio: 75.1% | Off-exchange volume (dark pool + OTC)
Apr 28, 2026
short_volume
Short Volume: RMD — 70.3% short (0.4M / 0.5M)
Short: 369,462 | Exempt: 200 | TRF Vol: 525,277 | Short Ratio: 70.3% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: RMD — 66.0% short (0.4M / 0.6M)
Short: 364,519 | Exempt: 32 | TRF Vol: 552,056 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
dark_pool
Dark Pool: RMD — 3.2M shares, 89,855 trades
Week starting 2026-04-27. Total ATS volume: 3,233,358 shares across 89,855 trades.
Apr 24, 2026
short_interest
FTD: RMD — 14,260 shares ($3.1M) failed to deliver
Settlement: 20260424, Price: $219.51, FTD Value: $3,130,212.6, RESMED INC
Apr 22, 2026
short_interest
FTD: RMD — 56,021 shares ($12.4M) failed to deliver
Settlement: 20260422, Price: $221.22, FTD Value: $12,392,965.62, RESMED INC